
Initiator Pharma Q2 - Financed to explore vulvodynia

Redeye provides a research update following the Q2 report recently published by Initiator Pharma. While the company is still awaiting a licensing deal for pudafensine within the ED indication, Initiator Pharma has now expanded its clinical pipeline into vulvodynia. Strengthened by the recent rights issue and the financial backing by MAC Clinical Research, the planned phase IIa trial marks a strategic move into female-focused indications with high unmet medical need and commercial potential. Following this, we make some changes to our valuation model. However, we reiterate our base case valuation of SEK15.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Initiator Pharma Q2 - Financed to explore vulvodynia